Novel RAAS agonists and antagonists: clinical applications and controversies. (Q38349798)

2 September 2017

title

Novel RAAS agonists and antagonists: clinical applications and controversies. (English)

1 reference

2 September 2017

Cesar A Romero

1 reference

2 September 2017

Marcelo Orias

series ordinal

1 reference

2 September 2017

Matthew R Weir

series ordinal

1 reference

2 September 2017

publication date

10 February 2015

1 reference

Nature Reviews Endocrinology

2 September 2017

published in

1 reference

2 September 2017

1 reference

2 September 2017

1 reference

2 September 2017

page(s)

242-252

1 reference

The existence of two forms of hypertensin

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Mechanism of pulmonary conversion of angiotensin I to angiotensin II in the dog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Historical Perspective of the Renin-Angiotensin System

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

The role of angiotensin II-stimulated renal tubular transport in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Renal proximal tubule angiotensin AT1A receptors regulate blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Chronic angiotensin II infusion drives extensive aldosterone-independent epithelial Na+ channel activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Mechanisms of mineralocorticoid action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

21 January 2018

Renin/prorenin receptors

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

The (pro)renin receptor. A decade of research: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

AT2 receptor agonists: hypertension and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Circulating aminopeptidase activities in men and women with essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Discovery of inhibitors of insulin-regulated aminopeptidase as cognitive enhancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Angiotensin IV-evoked vasoprotection is conserved in advanced atheroma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Role of angiotensin in ovarian follicular development and ovulation in mammals: a review of recent advances.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Physiology of local renin-angiotensin systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Inhibition of the renin-angiotensin system and target organ protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Sustained Effectiveness of Converting-Enzyme Inhibition in Patients with Severe Congestive Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

N-acetyl-seryl-aspartyl-lysyl-proline reduces cardiac collagen cross-linking and inflammation in angiotensin II-induced hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Guidelines for managing high blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Management of hypertension: summary of NICE guidance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

An Effective Approach to High Blood Pressure Control: A Science Advisory From the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Combined angiotensin inhibition for the treatment of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Efficacy of spironolactone therapy in patients with true resistant hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Natriuretic peptides in the regulation of the hypothalamic-pituitary-adrenal axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Molecular biology of the natriuretic peptide system: implications for physiology and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Biology of natriuretic peptides and their receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Angiotensin-neprilysin inhibition versus enalapril in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Antihypertensive and cardiorenal protective effects of SM-368229, a novel mineralocorticoid receptor antagonist, in aldosterone/salt-treated rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Investigation of aldosterone-synthase inhibition in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Aldosterone synthase inhibition in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

MicroRNA-24 is a novel regulator of aldosterone and cortisol production in the human adrenal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

21 January 2018

Oral renin inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Entry-into-humans study with a new direct renin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Effects of the renin inhibitor MK-8141 (ACT-077825) in patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Age and sex effects on the single- and multiple-dose safety and pharmacokinetics of the new renin inhibitor ACT-178882.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Angiotensin AT₂ receptor stimulation inhibits early renal inflammation in renovascular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

AT2-receptor stimulation enhances axonal plasticity after spinal cord injury by upregulating BDNF expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

AT₂ receptor activation induces natriuresis and lowers blood pressure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Angiotensin-converting enzyme 2: the first decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Human recombinant ACE2 reduces the progression of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Renoprotective Effects of AVE0991, a Nonpeptide Mas Receptor Agonist, in Experimental Acute Renal Injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Beneficial effects of the activation of the angiotensin-(1-7) MAS receptor in a murine model of adriamycin-induced nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

AVE 0991, a non-peptide Mas-receptor agonist, facilitates penile erection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

An orally active angiotensin-(1-7) inclusion compound and exercise training produce similar cardiovascular effects in spontaneously hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Oral administration of angiotensin-(1-7) ameliorates type 2 diabetes in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Insulin-regulated aminopeptidase is a key regulator of GLUT4 trafficking by controlling the sorting of GLUT4 from endosomes to specialized insulin-regulated vesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Identification and characterization of a new cognitive enhancer based on inhibition of insulin-regulated aminopeptidase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Vaccine for hypertension: modulating the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Construction, expression and immunogenicity of a novel anti-hypertension angiotensin II vaccine based on hepatitis A virus-like particle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2015.6

21 January 2018

Identifiers

DOI

10.1038/NRENDO.2015.6

1 reference

2 September 2017

1 reference